The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

INTRODUCTION: The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive impairment (MCI), and to assess effect modification by apolipoprotein E (APOE) g...

Descripción completa

Detalles Bibliográficos
Autores principales: Prins, Niels D, van der Flier, Wiesje A, Knol, Dirk L, Fox, Nick C, Brashear, H Robert, Nye, Jeffrey S, Barkhof, Frederik, Scheltens, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255389/
https://www.ncbi.nlm.nih.gov/pubmed/25478019
http://dx.doi.org/10.1186/alzrt275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255389/
https://www.ncbi.nlm.nih.gov/pubmed/25478019
http://dx.doi.org/10.1186/alzrt275

Ejemplares similares